Characteristics and treatment regimens across ERS SHARP severe asthma registries
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Characteristics and treatment regimens across ERS SHARP severe asthma registries. / van Bragt, Job J M H; Adcock, Ian M; Bel, Elisabeth H D; Braunstahl, Gert-Jan; Ten Brinke, Anneke; Busby, John; Canonica, Giorgio W; Cao, Hui; Chung, Kian Fan; Csoma, Zsuzsanna; Dahlén, Barbro; Davin, Elizabeth; Hansen, Susanne; Heffler, Enrico; Horvath, Ildiko; Korn, Stephanie; Kots, Maxim; Kuna, Piotr; Kwon, Namhee; Louis, Renaud; Plaza, Vicente; Porsbjerg, Celeste; Ramos-Barbon, David; Richards, Levi B; Škrgat, Sabina; Sont, Jacob K; Vijverberg, Susanne J H; Weersink, Els J M; Yasinska, Valentyna; Wagers, Scott S; Djukanovic, Ratko; Maitland-van der Zee, Anke H; SHARP Clinical Research Collaboration.
In: The European Respiratory Journal, Vol. 55, No. 1, 1901163, 2020.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Characteristics and treatment regimens across ERS SHARP severe asthma registries
AU - van Bragt, Job J M H
AU - Adcock, Ian M
AU - Bel, Elisabeth H D
AU - Braunstahl, Gert-Jan
AU - Ten Brinke, Anneke
AU - Busby, John
AU - Canonica, Giorgio W
AU - Cao, Hui
AU - Chung, Kian Fan
AU - Csoma, Zsuzsanna
AU - Dahlén, Barbro
AU - Davin, Elizabeth
AU - Hansen, Susanne
AU - Heffler, Enrico
AU - Horvath, Ildiko
AU - Korn, Stephanie
AU - Kots, Maxim
AU - Kuna, Piotr
AU - Kwon, Namhee
AU - Louis, Renaud
AU - Plaza, Vicente
AU - Porsbjerg, Celeste
AU - Ramos-Barbon, David
AU - Richards, Levi B
AU - Škrgat, Sabina
AU - Sont, Jacob K
AU - Vijverberg, Susanne J H
AU - Weersink, Els J M
AU - Yasinska, Valentyna
AU - Wagers, Scott S
AU - Djukanovic, Ratko
AU - Maitland-van der Zee, Anke H
AU - SHARP Clinical Research Collaboration
N1 - Copyright ©ERS 2020.
PY - 2020
Y1 - 2020
N2 - Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
AB - Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.
U2 - 10.1183/13993003.01163-2019
DO - 10.1183/13993003.01163-2019
M3 - Journal article
C2 - 31601713
VL - 55
JO - The European Respiratory Journal
JF - The European Respiratory Journal
SN - 0903-1936
IS - 1
M1 - 1901163
ER -
ID: 257547281